Forty Seven, Inc.
|Number of Estimates|
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
Market Cap: 1.87 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 48 Million
Float: 27 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 257 trading days
From: 2018-12-14 To: 2019-12-06
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|